FDA Approved of Modeyso (Dordaviprone) – A Milestone for Diffuse Midline Glioma
U.S. Food and Drug Administration (FDA) granted full approval to Modeyso (generic name: dordaviprone), a groundbreaking therapy for diffuse midline glioma (DMG) — a rare and highly aggressive brain tumor that primarily affects children, adolescents, and young adults. This marks the first time a systemic (body-wide) therapy has been approved for this devastating disease, representing a pivotal advance in neuro-oncology.